ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Above 50-Day Moving Average – Time to Sell?

ProQR Therapeutics N.V. (NASDAQ:PRQR)’s share price passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $1.63 and traded as high as $1.7850. ProQR Therapeutics shares last traded at $1.76, with a volume of 1,168,735 shares changing hands.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on PRQR shares. JonesTrading decreased their price objective on ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a report on Friday, June 26th. Weiss Ratings cut ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 23rd. Citigroup reaffirmed a “market outperform” rating on shares of ProQR Therapeutics in a research report on Wednesday, May 27th. Wall Street Zen cut shares of ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, Chardan Capital lowered their price objective on shares of ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, June 26th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, ProQR Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $7.33.

ProQR Therapeutics Price Performance

The stock has a market capitalization of $190.71 million, a P/E ratio of -3.62 and a beta of 0.04. The stock’s 50-day simple moving average is $1.64 and its 200 day simple moving average is $1.66.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings data on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.15). The firm had revenue of $2.35 million during the quarter, compared to the consensus estimate of $5.19 million. ProQR Therapeutics had a negative net margin of 331.33% and a negative return on equity of 84.87%. As a group, analysts expect that ProQR Therapeutics N.V. will post -0.52 earnings per share for the current fiscal year.

Insider Buying and Selling at ProQR Therapeutics

In other news, Director Bart Filius acquired 150,000 shares of the stock in a transaction on Friday, June 26th. The shares were purchased at an average price of $1.54 per share, for a total transaction of $231,000.00. Following the transaction, the director directly owned 150,000 shares of the company’s stock, valued at approximately $231,000. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Boer Daniel Anton De bought 150,000 shares of the company’s stock in a transaction dated Thursday, July 9th. The shares were purchased at an average cost of $1.74 per share, with a total value of $261,000.00. Following the acquisition, the chief executive officer directly owned 300,000 shares of the company’s stock, valued at approximately $522,000. This represents a 100.00% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 450,000 shares of company stock worth $730,500 in the last quarter. Company insiders own 8.40% of the company’s stock.

Institutional Trading of ProQR Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Osaic Holdings Inc. raised its holdings in ProQR Therapeutics by 59.6% in the 2nd quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 4,500 shares in the last quarter. Persistent Asset Partners Ltd grew its holdings in shares of ProQR Therapeutics by 24.5% during the 4th quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company’s stock worth $91,000 after purchasing an additional 8,874 shares in the last quarter. Diadema Partners LP increased its position in shares of ProQR Therapeutics by 6.2% in the fourth quarter. Diadema Partners LP now owns 167,532 shares of the biopharmaceutical company’s stock worth $338,000 after purchasing an additional 9,838 shares during the period. Bank of America Corp DE increased its position in shares of ProQR Therapeutics by 6.4% in the first quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company’s stock worth $300,000 after purchasing an additional 11,186 shares during the period. Finally, Raymond James Financial Inc. raised its stake in ProQR Therapeutics by 15.2% in the third quarter. Raymond James Financial Inc. now owns 110,270 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 14,549 shares in the last quarter. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.